Kytopen Raises Series B to Scale Cell Therapy Manufacturing Platform

Funding from Telegraph Hill Partners to accelerate global expansion and drive adoption of Flowfect technology.

Apr. 10, 2026 at 2:25pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life photograph featuring a sleek, modern laboratory beaker filled with a glowing blue liquid, symbolizing the precision and innovation behind Kytopen's cell therapy engineering platform.Kytopen's advanced cell engineering technology aims to streamline the manufacturing process and make potentially curative cell therapies more accessible.Cambridge Today

Kytopen, a Cambridge-based company specializing in non-viral cellular engineering, has announced a Series B financing round led by Telegraph Hill Partners. The funding will support Kytopen's global expansion across the U.S. and Europe while driving broader adoption of its Flowfect® technology platform, which integrates mechanical, electrical, and chemical forces to rapidly modify cells at large scale.

Why it matters

Kytopen's technology aims to improve the scalability, consistency, and cost-efficiency of cell therapy manufacturing, which is essential for advancing next-generation cell therapies and making them more accessible to the broader community.

The details

Kytopen's Flowfect Tx® GMP and Flowfect Discover™ systems are designed to streamline the process from early-stage feasibility through clinical and commercial manufacturing. The platform is built to integrate into closed GMP workflows and supports a wide range of cell therapy modalities.

  • Kytopen announced the Series B financing round on April 10, 2026.

The players

Kytopen

A Cambridge, Massachusetts-based company that specializes in non-viral, continuous flow cellular engineering technology.

Telegraph Hill Partners

A venture capital firm that led Kytopen's Series B financing round and will join the company's board of directors.

Michael Chiu

The CEO of Kytopen.

Matthew Mackowski

The Chairman and Managing Director of Telegraph Hill Partners.

Got photos? Submit your photos here. ›

What they’re saying

“Kytopen's Flowfect technology has demonstrated the ability to genetically modify a broad range of therapeutic cell types in higher quantities, with better cell health and with lower cost than existing methods. Adoption of technologies like Kytopen's will be essential to achieving broader community access to potentially curative cell therapies by lowering costs, shortening turn-around-time, and reducing variability.”

— Matthew Mackowski, Chairman and Managing Director, Telegraph Hill Partners

“We welcome Telegraph Hill Partners to our investor base at this pivotal stage. With strong and growing customer demand, this investment enables us to scale globally while continuing to invest in the infrastructure needed to support our partners in delivering cost-effective, advanced cell therapies worldwide.”

— Michael Chiu, CEO, Kytopen

What’s next

Kytopen plans to use the Series B funding to accelerate its global expansion across the U.S. and Europe, as well as drive broader adoption of its Flowfect technology platform.

The takeaway

Kytopen's innovative cellular engineering technology has the potential to significantly improve the scalability, consistency, and cost-efficiency of cell therapy manufacturing, which could help make these potentially curative treatments more accessible to a wider patient population.